• Takeda presented detailed Phase 2/3 IgGNITE results for investigational subcutaneous TAK-881 in primary immunodeficiency disease at ESID 2026.
• The study met its primary endpoint, supporting comparability to Takeda’s marketed HYQVIA in patients aged 16 and older.
• Descriptive findings indicated similar infection protection, safety, and tolerability to HYQVIA, with no new safety signals.
• TAK-881 could reduce administration burden versus HYQVIA, with shorter infusions and fewer infusion sites enabled by lower volume dosing.
• Regulatory submissions in the US, EU, and Japan are planned in fiscal 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610140800BIZWIRE_USPR_____20261014_BW178348) on October 14, 2026, and is solely responsible for the information contained therein.